Xeloda and Obstruction - a phase IV clinical study of FDA data

Summary:

Obstruction is reported as a side effect among people who take Xeloda (capecitabine), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Taxotere, and have Fungal infection.

The phase IV clinical study analyzes which people have Obstruction when taking Xeloda. It is created by eHealthMe based on reports of 46,293 people who have side effects when taking Xeloda from the FDA, and is updated regularly.

What is Xeloda?

Xeloda has active ingredients of capecitabine. It is often used in colon cancer. eHealthMe is studying from 46,649 Xeloda users. Check the latest studies of Xeloda.

What is Obstruction?

Obstruction is found to be associated with 475 drugs and 642 conditions by eHealthMe. Check the latest studies of Obstruction.

On Jul, 16, 2026

46,293 people reported to have side effects when taking Xeloda.
Among them, 26 people (0.06%) have Obstruction.

Among these 26 people:

How long have people been on Xeloda when they have Obstruction? *

What is the gender of people who have Obstruction when taking Xeloda? *

female: 71.43 %
male: 28.57 %

What is the age of people who have Obstruction when taking Xeloda? *

What are other drugs people take besides Xeloda? *

What are other side effects people have besides Obstruction? *

Nausea (feeling of having an urge to vomit): 10 people, 38.46%
Unilateral Hydronephrosis (kidney stone that causes obstruction of the ureter): 9 people, 34.62%
Death: 9 people, 34.62%
Hypoaesthesia (reduced sense of touch or sensation): 9 people, 34.62%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 8 people, 30.77%
Dizziness: 8 people, 30.77%
General Physical Health Deterioration (weak health status): 8 people, 30.77%
Pain: 8 people, 30.77%
Hot Flush (sudden feelings of heat): 8 people, 30.77%
Insomnia (sleeplessness): 8 people, 30.77%

What are the existing conditions these people have? *

Fungal Infection: 7 people, 26.92%
Rectal Cancer (cancer of rectum): 2 people, 7.69%
Malignant Respiratory Tract Neoplasm (cancer tumour of respiratory tract): 2 people, 7.69%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 3.85%
Rectosigmoid Cancer (cancer that originates in the rectum and sigmoid colon): 1 person, 3.85%
Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 1 person, 3.85%
Neuroendocrine Tumor: 1 person, 3.85%
Metastases To Liver (cancer spreads to liver): 1 person, 3.85%
Memory Loss: 1 person, 3.85%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Xeloda and have Obstruction?

- Check whether Obstruction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xeloda:

Xeloda (46,649 reports)

Obstruction treatments and more:

Obstruction (4,654 reports)

Browse all side effects of Xeloda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Obstruction:

Obstruction (475 drugs)

Browse all the conditions that are associated with Obstruction:

Obstruction (642 conditions)

Related publications that referenced our studies

Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on capecitabine (the active ingredients of Xeloda) and Xeloda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.